New EU GMP Rules for Vet Medicines Come in Force, Major Regulatory Shift for AH Industry

European Union Introduces Dedicated GMP Framework for Veterinary Medicines

A major regulatory milestone has come into effect across the European Union, with veterinary pharmaceutical manufacturers and active ingredient suppliers now operating under a new Good Manufacturing Practice (GMP) framework developed specifically for veterinary medicinal products.

Effective 16 July 2026, the new legislation replaces the long-standing practice of applying the same GMP guidance used for both human and veterinary medicines. Instead, veterinary medicines now have their own legally binding manufacturing regulations under the EU Veterinary Medicinal Products Regulation.

The change represents one of the most significant regulatory developments for Europe’s animal health industry in recent years and affects manufacturers, contract manufacturing organisations, importers and suppliers of veterinary active pharmaceutical ingredients (APIs) throughout the European Union.

Separate GMP Rules for Veterinary Medicines

For many years, veterinary medicines were manufactured under GMP guidance contained in EudraLex Volume 4, which was shared with human pharmaceutical products.

Under the new regulatory framework, veterinary medicines now follow dedicated implementing regulations specifically designed for the animal health sector. The legislation establishes legally enforceable GMP requirements for:

• Veterinary medicinal products

• Active pharmaceutical ingredients (APIs)

• Manufacturing quality systems

• Quality assurance procedures

• Batch certification and release

• Documentation and record keeping

• Validation and qualification

• Inspection readiness

The regulations apply directly across all EU Member States without requiring national legislation, creating a harmonised manufacturing framework for veterinary pharmaceutical production.

Stronger Quality Systems Across the Supply Chain

The new rules reinforce many of the quality principles already familiar to pharmaceutical manufacturers while placing them within a veterinary-specific legal framework. Manufacturers are expected to maintain comprehensive pharmaceutical quality systems that ensure medicines are consistently produced and controlled according to approved quality standards.

The regulations also strengthen oversight of manufacturing processes through enhanced requirements for:

• Risk management

• Process validation

• Supplier qualification

• Documentation integrity

• Personnel training

• Equipment qualification

• Change control

• Quality oversight

The objective is to improve consistency in veterinary medicine manufacturing throughout the European Union while maintaining high standards of product quality and patient safety.

Greater Focus on Active Pharmaceutical Ingredients

One of the important features of the new framework is the introduction of dedicated GMP requirements for active pharmaceutical ingredients (APIs) used in veterinary medicines. Manufacturers must demonstrate robust control over API sourcing, production and quality management throughout the manufacturing process.

Improved traceability and supplier oversight are expected to strengthen confidence in veterinary pharmaceutical supply chains and support regulatory inspections across multiple Member States.

Harmonised Rules Across Europe

The regulations are designed to create a consistent regulatory environment for veterinary medicine manufacturers operating within the European Union.

By replacing guidance-based requirements with directly applicable legislation, the EU aims to reduce regulatory variation between Member States while providing greater legal clarity for manufacturers and inspectors. Industry experts believe this harmonised approach will support:

• More consistent GMP inspections

• Greater regulatory certainty

• Improved manufacturing oversight

• Better alignment between manufacturers operating across multiple countries

• Stronger quality management throughout the veterinary pharmaceutical sector

What It Means for Manufacturers

Although many of the technical GMP principles remain familiar, companies manufacturing veterinary medicines have been required to review their quality management systems to ensure compliance with the new legal framework.

Manufacturers producing both human and veterinary medicines may now need to operate under separate GMP systems, with dedicated documentation, procedures and regulatory compliance processes for veterinary products. The transition has prompted many companies to update:

• Standard operating procedures

• Site Master Files

• Training programmes

• Validation documentation

• Supplier qualification programmes

• Internal audit systems

Why This Matters for the Global Animal Health Industry

The European Union remains one of the world’s largest markets for veterinary pharmaceuticals. Changes to EU manufacturing standards often influence regulatory expectations in other regions and are closely monitored by international animal health companies.

For manufacturers exporting veterinary medicines to Europe, maintaining compliance with EU GMP requirements is essential for continued market access.

The new framework also supports the broader objectives of the EU Veterinary Medicinal Products Regulation by strengthening manufacturing quality, improving regulatory consistency and reinforcing confidence in veterinary medicines supplied throughout the European market.

Looking Ahead

The introduction of dedicated veterinary GMP regulations marks a new chapter for Europe’s animal health sector. While the new framework does not fundamentally change the scientific principles of pharmaceutical quality, it provides, for the first time, a single, legally binding GMP system designed exclusively for veterinary medicinal products and their active ingredients.

As manufacturers complete the transition to the new requirements, the regulations are expected to strengthen quality assurance, improve regulatory consistency and support the long-term resilience of veterinary medicine manufacturing across the European Union.